stockmarketproxy
/
GHNasdaq SEC EDGAR

Guardant Health, Inc.

Services-Medical Laboratories·PALO ALTO, CA·FY end 12/31·CIK 1576280
OverviewFinancialsCompensationGovernanceInsidersFilings

Financials

5-year history · USD
MetricFY 2025FY 2024FY 2023FY 2022FY 2021Trend
Revenue$982.0M$739.0M$563.9M$449.5M$373.7M
Gross Profit——————
Operating Income-$437.2M-$443.6M-$564.7M-$544.4M-$411.0M
Net Income-$416.3M-$436.4M-$479.4M——
Operating CF-$184.8M-$239.9M-$325.0M-$309.5M-$209.0M
Capex$48.3M$35.1M$20.5M$77.5M$75.0M
Free Cash Flow-$233.1M-$274.9M-$345.5M-$386.9M-$284.1M
Buybacks$45.0M—————
Dividends——————
Gross Margin——————
Operating Margin-44.5%-60.0%-100.1%-121.1%-110.0%
Net Margin-42.4%-59.0%-85.0%——
FCF Margin-23.7%-37.2%-61.3%-86.1%-76.0%
R&D / Revenue37.1%47.1%65.1%83.2%70.4%
Effective Tax0.3%-0.3%-0.1%-0.2%-0.1%
Debt / Equity-15.14—————
Buybacks / FCF-19.3%—————

Peer comparison

Services-Medical Laboratories · 3 peers
CEO Pay Ratio
GH
44:1
DGX
275:1
NTRA
101:1
LH
292:1
CEO total comp
GH
—
DGX
$15M
NTRA
$15M
LH
—
Net Margin
GH
-42.4%
DGX
9.0%
NTRA
-9.0%
LH
6.3%